PlainPharmaWatch

CMS Open Payments · Tool

Onkos Surgical, Inc. vs Geistlich Pharma, North America, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Onkos Surgical, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 915, versus 122 for the other company. Its single largest recorded recipient represents 0.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Onkos Surgical, Inc.
HHI 915 · top recipient 0.1%
Ranked #1,063 of 1,838 companies by HHI
Geistlich Pharma, North America, Inc.
HHI 122 · top recipient 0.1%
Ranked #1,655 of 1,838 companies by HHI

Payment Overview

Total Payments
$402.3K
% of Industry
0.0%
Transactions
461
Avg per Transaction
$872.64
Recipients
461
Avg per Recipient
$872.64
Payment Types
4
Top Payment Type
Royalty or License
Total Payments
$401.7K
% of Industry
0.0%
Transactions
2,560
Avg per Transaction
$156.90
Recipients
2,543
Avg per Recipient
$157.95
Payment Types
4
Top Payment Type
Food and Beverage

Highlighted values indicate the higher figure for each metric.

Total payments compared

Onkos Surgical, Inc. vs Geistlich Pharma, North America, Inc. - total reported payments in CMS Open Payments PY2024

Onkos Surgical, Inc.$402.3KGeistlich Pharma, North Ame…$401.7K

Payment Types Breakdown

Onkos Surgical, Inc.

Royalty or License $221.0K

54.9%

Consulting Fee $142.5K

35.4%

Food and Beverage $27.8K

6.9%

Travel and Lodging $11.0K

2.7%

Geistlich Pharma, North America, Inc.

Food and Beverage $142.6K

35.5%

Travel and Lodging $73.9K

18.4%

Honoraria $28.5K

7.1%

Consulting Fee $10.0K

2.5%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Onkos Surgical, Inc.

  1. 1

    Jorge Casas

    $56,328.51 · 11 txns

  2. 2

    Kevin Andrew Raskin

    $55,988.80 · 5 txns

  3. 3

    Matthew J Seidel

    $55,225.92 · 5 txns

  4. 4

    Judd Edward Cummings

    $55,225.92 · 5 txns

  5. 5

    Steven Gitelis

    $37,902.09 · 6 txns

Geistlich Pharma, North America, Inc.

  1. 1

    LAWRENCE DIDOMENICO

    $13,000.00 · 2 txns

  2. 2

    DAVID URBANEK

    $12,473.00 · 33 txns

  3. 3

    SAMAR SHAIKH

    $10,306.90 · 17 txns

  4. 4

    MICHELLE BUTTERWORTH

    $6,621.69 · 2 txns

  5. 5

    ANDREW READ-FULLER

    $6,088.00 · 3 txns

Summary Comparison

Metric Onkos Surgical, Inc. Geistlich Pharma, North America, Inc.
Total Payments $402.3K $401.7K
% of Industry Total 0.0% 0.0%
Transaction Count 461 2,560
Avg per Transaction $872.64 $156.90
Recipient Count 461 2,543
Avg per Recipient $872.64 $157.95
Payment Type Count 4 4
Top Payment Type Royalty or License Food and Beverage

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.